21May 2024
Brexpiprazole Effective for Managing Agitation in Alzheimer’s Patients

Brexpiprazole Effective for Managing Agitation in Alzheimer’s Patients

A recent study assessed brexpiprazole's efficacy and safety in managing agitation among Alzheimer’s disease (AD) patients. Three studies involving 1,048 patients were analyzed. Brexpiprazole, at any dose, specifically at 2 mg, significantly improved agitation scores on the Cohen-Mansfield Agitation Inventory and Clinical Global Impression − Severity scale over 12 weeks. Incidence of treatment-emergent adverse events and all-cause mortality did not significantly differ between brexpiprazole and placebo groups. However, brexpiprazole administration was associated with increased scores on the Simpson-Angus Scale. These findings suggest brexpiprazole's efficacy in treating agitation in AD patients, though further research is needed to confirm long-term effects.

  • #neurology

Like

Save

Share